MLR Leaders and Agentic AI - What Matters, What Doesn’t

As AI adoption accelerates across life sciences, the conversation is shifting from experimentation to enterprise impact. In this thought-provoking vodcast, industry leaders examine agentic AI vs generative AI and what the distinction truly means for the future of the MLR review process in pharma.

Moving beyond content generation, the discussion explores how agentic AI architecture and agentic AI workflows can orchestrate decisions, enforce guardrails, and embed intelligence directly into MLR operations. The focus is not just on speed, but on strengthening MLR compliance, improving governance, and redesigning the MLR submission process with accountability built in.

The speakers also unpack how agentic AI in pharma enables scalable MLR solutions that align with pharma commercialization priorities, while preserving rigorous human-in-the-loop workflows. For organizations rethinking the MLR process pharma teams rely on, this session offers strategic insight into how AI can transform MLR from a bottleneck into a competitive advantage.